PARP1 and neoplasm: PARP inhibitors seem to be a promising therapeutic strategy, as data from preclinical and clinical studies indicate that these agents not only block tumor growth when used as a monotherapy but can also enhance the response to treatment in SCLC by making cancer cells more sensitive to currently available treatment modalities, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy.